YouTube video by CRUK Manchester Institute

The Max Perutz Labs - one of Europe’s leading institutes for basic research in the life sciences - invite applications for a Full Professorship in Molecular Mechanisms of Disease. We are seeking outst...

Utilising novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research.

Scientific Data - MLOmics: Cancer Multi-Omics Database for Machine Learning

The 2025 Gordon Research Conference on Synthetic Lethality Approaches in Oncology will be held in Portland, Maine. Apply today to reserve your spot.

The 2025 Gordon Research Conference on Synthetic Lethality Approaches in Oncology will be held in Portland, Maine. Apply today to reserve your spot.

Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer...

Tumor cells upregulate compensatory buffering genes following tumor suppressor loss. These genes may represent new synthetic lethal partners that could be harnessed therapeutically.

High-content phenotypic screens provide a powerful strategy for studying biological systems, but the scale of possible perturbations and cell states makes exhaustive experiments unfeasible. Computatio...

An engineered Cas12a enables higher-order combinatorial functional genomic screens using CRISPR interference.

Jo McEntyre will become Interim Director of EMBL-EBI as Ewan Birney takes up the role of EMBL Executive Director.

The 2025 Gordon Research Conference on Synthetic Lethality Approaches in Oncology will be held in Portland, Maine. Apply today to reserve your spot.

Gene dynamics of concurrent biological processes are unraveled by considering gene trajectories instead of cell trajectories.

Scientists rally across the country in response to layoffs and funding cuts ordered by the Trump administration

Celebrating and supporting the achievements of women in science, and all those who work to encourage girls and young women to engage with STEM subjects and stay in STEM careers around the world.

Metastasis is the leading cause of cancer deaths; nonetheless, how tumor cells adapt to vastly different organ contexts is largely unknown. To investigate this question, we generated a transcriptomic ...

Tumor cells upregulate compensatory buffering genes following tumor suppressor loss. These genes may represent new synthetic lethal partners that could be harnessed therapeutically.

The 2025 Gordon Research Conference on Synthetic Lethality Approaches in Oncology will be held in Portland, Maine. Apply today to reserve your spot.

Building predictive models of the cell requires systematically mapping how perturbations reshape each cell's state, function, and behavior. Here, we present Tahoe-100M, a giga-scale single-cell atlas of 100 million transcriptomic profiles measuring how each of 1,100 small-molecule perturbations impact cells across 50 cancer cell lines. Our high-throughput Mosaic platform, composed of a highly diverse and optimally balanced 'cell village', reduces batch effects and enables parallel profiling of thousands of conditions at single-cell resolution at an unprecedented scale. As the largest single-cell dataset to date, Tahoe-100M enables artificial-intelligence (AI)-driven models to learn context-dependent functions, capturing fundamental principles of gene regulation and network dynamics. Although we leverage cancer models and pharmacological compounds to create this resource, Tahoe-100M is fundamentally designed as a broadly applicable perturbation atlas and supports deeper insights into cell biology across multiple tissues and contexts. By publicly releasing this atlas, we aim to accelerate the creation and development of robust AI frameworks for systems biology, ultimately improving our ability to predict and manipulate cellular behaviors across a wide range of applications. ### Competing Interest Statement Jesse Zhang, Airol A Ubas, Richard de Borja, Valentine Svensson, Nicole Thomas, Neha Thakar, Ian Lai, Aidan Winters, Umair Khan, Matthew G. Jones, Daniele Merico, Nima Alidoust, Hani Goodarzi, Johnny Yu, have received compensation and/or equity from Vevo Therapeutics. Vuong Tran, Joseph Pangallo, Efthymia Papalexi, Ajay Sapre, Hoai Nguyen, Oliver Sanderson, Maria Nigos, Olivia Kaplan, Sarah Schroeder, Bryan Hariadi, Simone Marrujo, Crina Curca Alec Salvino, Guillermo Gallareta Olivares, Ryan Koehler, Gary Geiss, Alexander Rosenberg, Charles Roco, have received compensation and/or equity from Parse Biosciences.